RespireRx Pharmaceuticals (RSPI) Short Interest Ratio & Short Volume

Short interest is the volume of RespireRx Pharmaceuticals shares that have been sold short but have not yet been covered or closed out. As of February 15th, investors have sold 166,600 shares of RSPI short. 0.04% of RespireRx Pharmaceuticals' shares are currently sold short. Learn More on RespireRx Pharmaceuticals' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.04% of RespireRx Pharmaceuticals' floating shares are currently sold short.

RespireRx Pharmaceuticals saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 166,600 shares, an increase of 107.0% from the previous total of 80,500 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

0.04% of RespireRx Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies compare to RespireRx Pharmaceuticals: Inhibitor Therapeutics, Inc. (0.00%), Indaptus Therapeutics, Inc. (1.02%), Apollomics, Inc. (1.73%), American Premium Mining Co. (0.00%), NeuroBo Pharmaceuticals, Inc. (1.14%), Aytu BioPharma, Inc. (1.98%), Lipella Pharmaceuticals Inc. (0.91%), Genprex, Inc. (6.94%), GT Biopharma, Inc. (2.27%), Palatin Technologies, Inc. (29.27%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Invesco QQQ ($25.81 billion), iShares 20+ Year Treasury Bond ETF ($10.38 billion), Strategy Incorporated ($7.74 billion), AppLovin Co. ($6.32 billion), Apollo Global Management, Inc. ($5.97 billion), Super Micro Computer, Inc. ($4.89 billion), Charter Communications, Inc. ($4.52 billion), Capital One Financial Co. ($3.94 billion), Schlumberger Limited ($3.19 billion), and Reddit, Inc. ($3.01 billion). View all of the most shorted stocks.

Short selling RSPI is an investing strategy that aims to generate trading profit from RespireRx Pharmaceuticals as its price is falling. RSPI shares are trading up $0.00 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for RespireRx Pharmaceuticals occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of RSPI, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RSPI, twice per month. The most recent reporting period available is February, 15 2025.